Rapid Biosensor Systems spun off to provide rapid TB (tuberculosis) diagnosis
This article was originally published in Clinica
Executive Summary
A new company, Rapid Biosensor Systems (RBS), has been spun out of UK technology entrepreneurs Sentec in order to commercialise patented technology for the rapid screening of tuberculosis (TB). Under CEO Dennis Camilleri, RBS will have complete autonomy as it develops its own IP and generates income from licensing deals, which it hopes to form from global healthcare organisations.